New President of CellaVision North America
(Thomson Reuters ONE) -
CellaVision AB (publ) has appointed Peter Wilson as President CellaVision North
America with responsibility for operations in the U.S. and Canada. Peter Wilson
currently holds a position as Marketing Manager and is part of the CellaVision
Management Team. He will begin his new position on September 1, 2012.
Peter Wilson will be responsible for CellaVision operations in North America
which includes the two subsidiaries in the United States and Canada, and will
report directly to Yvonne Mårtensson, President and CEO of CellaVision AB. The
subsidiaries' function is sales, marketing and support to partners and end
customers.
"I am very pleased that Mr. Wilson will lead CellaVision's sales and marketing
efforts in North America. Peter has held several key roles in CellaVision since
2000 and has extensive experience in the company, our markets, competitors and
customers. In North America, our focus on partnerships in parallel with our own
sales organization has had a significant impact on our sales success, and Peter
has an excellent position to continue developing the business forward," says
Yvonne Mårtensson, President and CEO of CellaVision.
Peter Wilson holds a Master of Science in Chemical Engineering. He has many
years' experience in global commercialization of new technologies and products.
For the past ten years he has held senior positions at the marketing department
of CellaVision, of which the last five years from a position of the management
team. Before CellaVision he worked at Foss, a supplier of laboratory equipment
for the food and grain industry, including positions in the U.S. He succeeds
Dave Autry, who led the business since 2009.
North America is CellaVision's most important growth market. In 2011, the market
developed well and represented approximately 60 percent of the company's total
sales. In the U.S. CellaVision sells through the distributors Sysmex and Beckman
Coulter, both global leaders in the hematology market, and through support of
CellaVision's own sales organization. In Canada CellaVision sells directly
through its own subsidiary.
For further information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. Email: yvonne.martensson(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The analyses often constitute important
reference data for fast and correct diagnosis of illnesses, for example of
infections and serious cancers. CellaVision's products rationalize manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. The company has leading-edge expertise
in image analysis, artificial intelligence and automated microscopy. In 2011
sales were SEK 155 million and sales continue to increase, with a growth target
of at least 15 % per year over an economic cycle. CellaVision's registered
office is in Lund and the company has subsidiaries in the USA, Canada and Japan.
The share is listed on the Nasdaq, OMX Stockholm, Small Cap list. Read more at
www.cellavision.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1619263]
Unternehmensinformation / Kurzprofil:
Datum: 13.06.2012 - 10:01 Uhr
Sprache: Deutsch
News-ID 155929
Anzahl Zeichen: 4092
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New President of CellaVision North America"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
